Ponesimod
- Generic Name
- Ponesimod
- Brand Names
- Ponvory
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25ClN2O4S
- CAS Number
- 854107-55-4
- Unique Ingredient Identifier
- 5G7AKV2MKP
- Background
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be respons...
- Indication
Ponesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
A Study of Ponesimod in Healthy Adult Participants
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 28
- Registration Number
- NCT05552196
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Actelion
- Target Recruit Count
- 877
- Registration Number
- NCT03232073
- Locations
- 🇧🇬
Military Medical Academy Multiprofile Hospital for Active Treatment Sofia, Sofia, Bulgaria
🇨🇿Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia
🇨🇿Pardubicka krajska nemocnice a s, Pardubice, Czechia
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Actelion
- Target Recruit Count
- 136
- Registration Number
- NCT02907177
- Locations
- 🇺🇸
Associated Neurologists, Danbury, Connecticut, United States
🇺🇸Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸OhioHealth Research Institute, Columbus, Ohio, United States
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Actelion
- Target Recruit Count
- 1
- Registration Number
- NCT02461134
- Locations
- 🇺🇸
Fred Hutchinson Cancer Res CTR, Seattle, Washington, United States
🇺🇸Virginia Piper Cancer Institute, Scottsdale, Arizona, United States
🇺🇸Moore Cancer Center - UCSD, La Jolla, California, United States
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Actelion
- Target Recruit Count
- 1133
- Registration Number
- NCT02425644
- Locations
- 🇮🇱
Investigator Site 4006, Jerusalem, Israel
🇵🇹Investigator Site 1604, Porto, Portugal
🇲🇽Investigator Site 7410, Chihuahua, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.